Journal of palliative medicine · 2025
Assessing Quality of Life in Patients with Pancreatic Cancer in a Prospective Single-Center Observational Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miinalainen Sofia, Löyttyniemi Eliisa, Jyrkkiö Sirkku, Akrén Outi
Аннотация
BACKGROUND AND PURPOSE: Patients with pancreatic cancer have an extensive symptom burden and a modest quality of life (QoL). Our aim was to evaluate three QoL questionnaires in clinical practice and monitor patients' symptoms over a 4-month follow-up period.
MATERIALS AND METHODS: The study included 54 patients with pancreatic cancer in a single-center University Hospital in Finland. The QoL questionnaires involved were the European Organization for Research and Treatment of Cancer QLQ-C15-PAL, QLQ-C30, and QLQ-PAN26. Patients completed the questionnaires at baseline and at 2 and 4 months.
RESULTS: All three questionnaires served as a tool for facilitating dialogue between patient and physician. No relevant changes were observed in reported symptoms, concerns, or QoL during the follow-up period. However, the amount of missing data increased over time due to patients' declining health or death. The main reported concern was worry about future health.
CONCLUSION: The shorter 15-question survey seemed to capture an adequate picture of patient well-being. The QLQ-PAN26 added valuable insight, as it focuses on pancreatic cancer-related symptoms. The information gathered from these QoL questionnaires can be used both to emphasize patients' concerns and to support decision making.
MATERIALS AND METHODS: The study included 54 patients with pancreatic cancer in a single-center University Hospital in Finland. The QoL questionnaires involved were the European Organization for Research and Treatment of Cancer QLQ-C15-PAL, QLQ-C30, and QLQ-PAN26. Patients completed the questionnaires at baseline and at 2 and 4 months.
RESULTS: All three questionnaires served as a tool for facilitating dialogue between patient and physician. No relevant changes were observed in reported symptoms, concerns, or QoL during the follow-up period. However, the amount of missing data increased over time due to patients' declining health or death. The main reported concern was worry about future health.
CONCLUSION: The shorter 15-question survey seemed to capture an adequate picture of patient well-being. The QLQ-PAN26 added valuable insight, as it focuses on pancreatic cancer-related symptoms. The information gathered from these QoL questionnaires can be used both to emphasize patients' concerns and to support decision making.